$100M Share Offering Priced by MeiraGTx to Fund Pipeline Through 2028
Event summary
- $100M offering of 11,111,111 ordinary shares priced at $9.00 per share.
- Proceeds expected to fund operations through potential commercial launches in H2 2028.
- Offering managed by BofA Securities and Goldman Sachs as joint book-runners.
- Expected closing on April 17, 2026, subject to customary conditions.
The big picture
MeiraGTx's $100M share offering underscores the capital-intensive nature of genetic medicine development. The proceeds will extend its runway into 2028, a critical period for potential commercial launches of bota-vec and AAV-hAQP1. This move reflects broader industry trends where clinical-stage biotechs rely on strategic financings to bridge gaps between R&D and market readiness.
What we're watching
- Execution Risk
- Whether MeiraGTx can deliver on its pipeline milestones by H2 2028.
- Market Dynamics
- How the $100M infusion positions MeiraGTx against competitors in genetic medicines.
- Regulatory Timelines
- The pace at which bota-vec and AAV-hAQP1 advance through approval processes.
Related topics